

Neurotech

5 December 2019

Neurotech Announces Mente Partnership with the Australian Neurofeedback Institute

New qEEG service enhances support for clinics using or recommending Mente in Australia

Malta and Perth, Australia - Neurotech International Limited (ASX: NTI) are pleased to announce a new partnership between Mente and the Australian Neurofeedback Institute (“ANFI”) which will bring together the advanced neuroscience skills of ANFI along with Mente’s clinically proven therapy for the Australian Market. ANFI as the centre of excellence collaborates with the research partners in academia, world leaders in mental health treatment and neuromodulation technology manufacturers to develop, deliver, expand and promote cutting edge treatments, client outcomes and industry training.

Under the first phase of the partnership, the team at ANFI will be providing qEEG services and expert analysis to support clinicians working with Mente. ANFI’s services and contact details are available at <https://development.anfi.org.au/neurofeedback-sessions/>.

Clinically proven Mente helps ASD children to learn to engage positively with their environment and self-regulate attention and mood. Mente is available through www.mentetech.com.

Neurotech CEO and Managing Director, Peter Griffiths, said: “We are delighted to be working alongside the experts at ANFI to support Australian clinics in offering qEEGs to customers. We believe our Mente users and the wider community will greatly benefit from ANFI’s clinical knowledge, analysis services, training, mentorship and research opportunities.”

ANFI Deputy Director, Sejla Murdoch, said: “We are excited to be working in collaboration with the Mente team. Mente’s cutting-edge approach enables neurofeedback therapy to be provided both in clinic and at home under a supervised clinical programme. We are looking forward to supporting clinics in improving outcomes for their clients. ANFI will provide the expert EEG Assessment to support the Mente treatment for children who come to our service.”

Authority

This announcement has been authorised for release by Peter Griffiths, CEO and Managing Director of Neurotech International Limited.

Further information

Peter Griffiths
CEO & Managing Director
peter.griffiths@mentetech.com

Judith Wilkinson
Media Enquiries
Judith.wilkinson@mentetech.com

-Ends-

Neurotech International Ltd

ABN 73 610 205 402
Suite 5 CPC, 145 Stirling Highway
Nedlands, Western Australia 6009
www.neurotechinternational.com

For personal use only

For personal use only

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism.

Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>

<http://www.mentetech.com>